Search

Search Results
Results 7401 - 7410 of 8185 for Skin Cancer
  • News - 28 Jan 2010
    Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, today unveiled its new clinical-grade, miniaturized electroporation device designed to be an easy-to-use,...
  • News - 6 Jan 2010
    Health Canada has approved Zyclara™ (imiquimod) Cream 3.75%, a topical prescription treatment for multiple actinic keratoses (AK) located on the face or balding scalp in adults. Actinic Keratosis is a...
  • News - 22 Dec 2009
    LEO Pharma today announced positive results for the company’s two Phase III actinic (solar) keratosis (AK) clinical trials using PEP005 (ingenol mebutate) Gel for the treatment of lesions on head...
  • News - 5 Feb 2008
    Amgen and Wyeth Pharmaceuticals, a division of Wyeth have announced findings from a retrospective analysis, which demonstrated that ENBREL reduced C-reactive protein (CRP), a marker of inflammation,...
  • Drug - 4 Oct 2024
    Consumer Medicine Information (CMI) about Stelara intended for persons living in Australia.
  • Drug - 30 Sep 2024
    Consumer Medicine Information (CMI) about Opsynvi intended for persons living in Australia.
  • Drug - 25 Sep 2024
    Consumer Medicine Information (CMI) about Viagra intended for persons living in Australia.
  • Drug - 16 Sep 2024
    Consumer Medicine Information (CMI) about Voranigo intended for persons living in Australia.
  • Drug - 11 Sep 2024
    Consumer Medicine Information (CMI) about Istodax intended for persons living in Australia.
  • Health - 10 Sep 2024
    Understanding inflammation's role in health is crucial, as it links to various diseases and can be managed through diet, exercise, and medical treatments.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.